Just ten months after its official launch, the MedVallée excellence hub in global health has already started working on 19 of its 30 assigned actions. Ten of those have already been completed. The ...
MedinCell and its partner TEVA announced that US FDA approuved UZEDY™, a long-acting injectable medication for treating schizophrenia. MedinCell also raised 25 million euros.
On April 28, the pharmaceutical company MedinCell and its partner TEVA announced that the US Food and Drug Administration (FDA) approved a long-acting injectable medication for treating schizophren...
By facilitating partnerships between research laboratories, companies, institutions, and health professionals, MedVallée – the hub for excellence in global health – has become a major catalyst for ...
Six months after the MedVallée Meetings in late June 2022, which brought together more than 700 stakeholders from MedVallée’s three areas of excellence, the beginning of 2023 is marked by a wealth ...
Futurapolis showed that MedVallée, world-class excellence cluster in Global Health, is gaining ground in an exemplary territory. Proof is in the actions presented by Montpellier, Montpellier Métrop...
For the Agri Sud-Ouest Innovation, Aqua-Valley, Derbi, and Eurobiomed clusters, MedVallée will foster projects and innovations thanks to the convergence of health, food, and environmental sectors f...
The new Thomas Platter building for biotherapies, located in the heart of the Montpellier CHU University Hospital, was presented on July 26.
